New Drug Applications

Thelin

sitaxsentan

Treatment for Pulmonary Arterial Hypertension (PAH)

Encysive Pharmaceuticals Receives Approvable Letter From FDA for Thelin

HOUSTON, March 24, 2006 -- Encysive Pharmaceuticals today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Thelin (sitaxsentan sodium), which is under review for the treatment of pulmonary arterial hypertension (PAH). The action letter contains concerns and observations that must be satisfied prior to achieving approval, including a request for additional clinical trial work.

"We will work in close collaboration with the FDA to clarify the path forward. We are hopeful that this can be accomplished without the need for additional clinical work, but that will require discussion with the Agency before we can be sure," said Bruce D. Given, M.D., President and Chief Executive Officer of Encysive Pharmaceuticals. "We remain confident in Thelin's value, and look forward to the opportunity to provide PAH patients with a new treatment option."

Source: Encysive Pharmaceuticals Inc.

Related Articles:

Encysive Pharmaceuticals Receives Written Response From FDA On Its Request for Formal Dispute Resolution for Thelin (Sitaxsentan Sodium) - September 6, 2007

Encysive Pharmaceuticals Files Request for Formal Dispute Resolution With U.S. FDA to Contest Third Approvable Letter for Thelin - August 7, 2007

Encysive Pharmaceuticals Provides Update for Thelin (Sitaxsentan Sodium) - July 13, 2007

FDA Issues Third Approvable Letter for Thelin (Sitaxsentan Sodium) - June 18, 2007

FDA Accepts Encysive’s Complete Response to Thelin New Drug Application - December 28, 2006

Encysive Pharmaceuticals Submits Response to FDA For Thelin New Drug Application - December 15, 2006

Encysive Expects to Submit Revised Response to Thelin Approvable Letter Within Several Days - December 14, 2006

Encysive Submits Complete Response to FDA For Thelin New Drug Application - November 2, 2006

FDA Issues Approvable Letter for Thelin; One Outstanding Item Remains - July 24, 2006

FDA Grants Class 1 Review to Encysive Pharmaceuticals’ Complete Response to Thelin NDA - June 15, 2006